Literature DB >> 11986227

Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.

Takashi Miwa1, Lin Zhou, Brendan Hilliard, Hector Molina, Wen-Chao Song.   

Abstract

Decay-accelerating factor (DAF) and CD59 are 2 glycosylphosphatidylinositol-anchored membrane proteins that inhibit complement activation at the C3 and C5b-9 step, respectively. CD59 is considered critical for protecting erythrocytes from spontaneous complement attack, as deficiency of CD59 or CD59/DAF, but not of DAF alone, on human erythrocytes renders them sensitive to complement lysis in paroxysmal nocturnal hemoglobinuria syndrome. To evaluate the relative roles of CD59 and DAF in vivo, we have generated and studied a CD59 knockout and a CD59/DAF double-knockout mouse. CD59-deficient and CD59/DAF-double-deficient mouse erythrocytes were highly sensitive to antibody-induced complement lysis in vitro, yet neither CD59 knockout nor CD59/DAF double-knockout mouse developed spontaneous hemolytic anemia. Consistent with the latter observation, erythrocytes from the 2 strains of mutant mice were shown to have a normal lifespan in vivo. In contrast, mouse erythrocytes deficient in complement receptor 1 (CR1)-related gene y (Crry), a membrane C3 inhibitor with DAF and membrane cofactor protein activities, were rapidly eliminated from the circulation by a complement-dependent mechanism. Compared with DAF-deficient erythrocytes, Crry-deficient erythrocytes incurred higher levels of spontaneous C3 deposition in vivo. These findings demonstrate that CD59 and DAF are not indispensable on murine erythrocytes. Rather, effective C3 regulation on the cell surface, provided by Crry rather than DAF, is necessary for mouse erythrocytes to resist spontaneous complement attack. Our results raise the possibility that proper control of C3 activation may also be critical on human erythrocytes, where CR1 but not DAF could be the principal regulator of spontaneous C3 activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986227     DOI: 10.1182/blood.v99.10.3707

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

2.  Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene.

Authors:  Hani Boshra; Wioleta M Zelek; Timothy R Hughes; Santiago Rodriguez de Cordoba; B Paul Morgan
Journal:  J Immunol       Date:  2017-11-22       Impact factor: 5.422

Review 3.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.

Authors:  Saifur R Ahmad; Elaine A Lidington; Rieko Ohta; Noriko Okada; Michael G Robson; Kevin A Davies; Michael Leitges; Claire L Harris; Dorian O Haskard; Justin C Mason
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

5.  Role of complement activation in obliterative bronchiolitis post-lung transplantation.

Authors:  Hidemi Suzuki; Mark E Lasbury; Lin Fan; Ragini Vittal; Elizabeth A Mickler; Heather L Benson; Rebecca Shilling; Qiang Wu; Daniel J Weber; Sarah R Wagner; Melissa Lasaro; Denise Devore; Yi Wang; George E Sandusky; Kelsey Lipking; Pankita Pandya; John Reynolds; Robert Love; Thomas Wozniak; Hongmei Gu; Krista M Brown; David S Wilkes
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

6.  CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice.

Authors:  Guipeng An; Takashi Miwa; Wen-Liang Song; John A Lawson; Daniel J Rader; Yun Zhang; Wen-Chao Song
Journal:  Mol Immunol       Date:  2009-03-17       Impact factor: 4.407

7.  Membrane protein Crry maintains homeostasis of the complement system.

Authors:  Xiaobo Wu; Dirk Spitzer; Dailing Mao; Stanford L Peng; Hector Molina; John P Atkinson
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

8.  Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.

Authors:  Yuko Kimura; Takashi Miwa; Lin Zhou; Wen-Chao Song
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

9.  Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.

Authors:  David D Kim; Takashi Miwa; Yuko Kimura; Reto A Schwendener; Menno van Lookeren Campagne; Wen-Chao Song
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

10.  Complement-dependent T-cell lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry.

Authors:  Takashi Miwa; Lin Zhou; Yuko Kimura; David Kim; Avinash Bhandoola; Wen-Chao Song
Journal:  Blood       Date:  2009-01-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.